Commercialization at UHN

Toronto, ON
Pre-SeedSeedRaiseTheNorth verification research (2026-09)

Investment Thesis

Commercialization at UHN is the research commercialization hub at University Health Network in Toronto that accelerates world-class medical discoveries toward maximum patient impact globally. The fund takes equity positions in spinouts derived from UHN's research, focusing on therapeutics, medical devices, diagnostics, and digital health platforms from pre-seed through seed stage. Successful exits including Trillium Therapeutics (Pfizer USD$2.22B), BlueRock Therapeutics (USD$1B), and ADELAP demonstrate proven ability to build category-defining companies from academic IP.

Focus Areas

Investment Stage
Pre-SeedSeed
Sectors
TherapeuticsMedTechDigital HealthBiotech

Investment Signals

GeographyCanada-focused
ProvincesON
RoleLead
Revenue Stagepre-revenue ok
Impact MandateYes
Business Modelsdeep-tech, therapeutics, medical devices, diagnostics, IP-licensing
Won't Invest Inbasic research

Sample Portfolio Companies

Avrobio
Trillium Therapeutics
BlueRock Therapeutics
ADELAP
Treadwell Therapeutics
Medly
TCRyption
Acumyn

AUM & Sources

N/A
Assets under management (estimated)
Sources
No public sources found.
Raising from Canadian VCs?Get AI-matched to your top investors in seconds.
Find My Investors →

Similar Funds

Toronto Innovation Acceleration Partners (TIAP)
Toronto, ON
Pre-SeedSeed
MEDTEQ+ Investment Fund
Montreal, QC
Pre-SeedSeed
TVM Capital Life Science
Montreal, QC
SeedSeries A
GTAN | Angel to Series A Investments
Waterloo Region, Ontario
Pre-SeedSeed

See incorrect information?

Help us keep this directory accurate and up to date.